Susceptibility of Bacterial Isolates From Turkey - A Report From the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program

References

• Aksaray S, Dokuzoguz B, Guvener E et al. Surveillance of antimicrobial resistance among gram-negative isolates from intensive care units in eight hospitals in Turkey. J Antimicrob Chemother 2000; 45: 695–699.
   Google Scholar
• Carlet J, Ben Ali A, Chalfine A. Epidemiology and con-trol of antibiotic resistance in the intensive care unit. Curr Opin Infect Dis 2004; 17: 309–316.
   PubMed Web of Science ®Google Scholar
• Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999; 281: 67–71.
   Google Scholar
• Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluo-roquinolone use. JAMA 2003; 289: 885–888.
   PubMed Web of Science ®Google Scholar
• Jones RN, Kehrberg EN, Erwin ME, Anderson SC. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group. Diagn Microbiol Infect Dis 1994; 19: 203–215.
   Google Scholar
• Bush K. New 13-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001; 32: 1085-1089.
   Google Scholar
• Livermore DM. 13-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557–584.
   PubMed Web of Science ®Google Scholar
• Medeiros AA. Evolution and dissemination of beta-lacta-mases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis 1997; 24 Suppl 1: S19–S45.
   PubMedGoogle Scholar
• Bax R, Bywater R, Cornaglia G, et al. Surveillance of antimicrobial resistance - what, how and whither? Clin Microbiol Infect 2001; 7: 316–325.
   PubMed Web of Science ®Google Scholar
• Turner PJ. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview. J Antimicrob Chemother 2000; 46 Suppl T2: 9–23.
   Web of Science ®Google Scholar
• Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128–140.
   PubMed Web of Science ®Google Scholar
• Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Am J Infect Control 1992; 20: 271–274.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Document M100-S10. NCCLS, Wayne, PA. 2001.
   Google Scholar
• Pfaller MA, Jones RN. Antimicrobial susceptibility of inducible AmpC 13-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. Int J Antimicrob Agents 2002; 19: 383–388.
   PubMed Web of Science ®Google Scholar
• Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis 2001; 41: 183–189.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Korten V, Jones RN, Doern GV. Multicenter evaluation of the antimicrobial activity for seven broad-spectrum I3-lactams in Turkey using the Etest method. Turkish Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999; 35: 65–73.
   PubMed Web of Science ®Google Scholar
• Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000; 45: 183–189.
   Google Scholar
• Hanberger H, Diekema D, Fluit A, et al. Surveillance of antibiotic resistance in European ICUs. J Hosp Infect 2001; 48: 161–176.
   PubMed Web of Science ®Google Scholar
• Kurt H, Eraksoy H. The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) study: first year results. In: Difficult-to-treat organisms isolated from two ICUs in Turkey. Rev Esp Quimioter 2000; 13 (Suppl. 2): 108 (abstract).
   Google Scholar
• Over U, Gur D, Unal S, Miller GH. The changing nature of aminoglycoside resistance mechanisms and preva-lence of newly recognized resistance mechanisms in Turkey. Clin Microbiol Infect 2001; 7: 470–478.
   PubMed Web of Science ®Google Scholar
• Gunseren F, Mamikoglu L, Ozturk S, et al. Surveillance study of antimicrobial resistance of gram-negative bacteria iso-lated from intensive care units in eight hospitals in Turkey. J Antimicrob Chemother 1999; 43: 373–378.
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez JA, Jones RN, MYSTIC Programme Study Group. Antimicrobial resistance in gram-negative iso-lates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme. J Chemother 2002; 14: 25–32.
   Google Scholar
• Fluit AC, Verhoef J, Schmitz FJ. Antimicrobial resistan-ce in European isolates of Pseudomonas aeruginosa. European SENTRY Participants. Eur J Clin Microbiol InfectDis 2000; 19: 370–374.
   PubMed Web of Science ®Google Scholar
• Masterton RG. Ciprofloxacin resistance-'early warning' signs from the MYSTIC surveillance programme? J Antimicrob Chemother 2002; 49 (1): 218–220.
   PubMedGoogle Scholar
• Jones RN, Pfaller MA. Ciprofloxacin as broad-spectrum empiric therapy—are fluoroquinolones still viable monothera-peutic agents compared with beta-lactams: data from the MYSTIC Program (US)? Diagn Microbiol Infect Dis 2002; 42: 213–215.
   PubMed Web of Science ®Google Scholar